25 October 2025 in Ophthalmology
GLGuilherme Melchior Maia Lopes
Guilherme Melchior Maia Lopes
MCMatheus Pedrotti Chavez
+2
23 July 2025 in European Journal of Ophthalmology
Background: Persistent epithelial defects (PEDs) are challenging corneal conditions with prolonged non-healing. Commonly associated with dry eye disease and neurotrophic keratopathy, PEDs can lead to severe complications. Topical insulin has emerged as a therapeutic option, promoting epithelial healing. Methods: We searched Medline, Embase, Web of Science, and Cochrane Library databases following PRISMA guidelines for studies reporting topical insulin for PEDs of any etiology and corneal epithelial defect (CEDs) post-vitrectomy. Healing time, complete wound healing (CWH), epithelization failure (EF), and epithelial healing rate were our analysis outcomes. Statistical analyses employed random-effects models and I² statistic. Results: Thirteen studies involving 390 eyes were included. Mean healing time for all conditions was 20.68 days (95% CI: 11.60, 29.76) with significant heterogeneity. The pooled CWH rate was 94% (95% CI: 0.87, 0.98), with an odds ratio of 5.41 favoring topical insulin over the control group. EF was low at 5% (95% CI: 0, 0.13), and the epithelial healing rate was 0.82 mm²/hour (95% CI: 0.02, 1.62). Subgroup analyses revealed variations. Conclusions: Topical insulin is effective in corneal wound healing, demonstrating high CWH rates and low failure rates. Further well-controlled studies are needed to validate these findings and assess long-term outcomes.
1 January 2021 in Ophthalmology
The National Diabetes Statistics Report 2020 estimates that of the 34.1 million adults in the USA with diabetes in 2018, 21.4% had undiagnosed disease.1 Due to an insidious disease course, diabetic complications like diabetic retinopathy (DR) are common. Among US diabetic adults, 28.5% have DR and 4.4% have vision-threatening DR.2 DR remains the leading cause of new […]
1 March 2026 in Clinical Ophthalmology
Purpose: To review and compare the efficacy and safety of adult and pediatric biologic biosimilar use for the treatment of noninfectious uveitis (NIU). Methods: A review of the literature from inception to December 2025 was conducted using Pubmed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), and Web of Science to identify studies that included data or discussion on the use of biosimilar biologic agents for adult and/or pediatric NIU. Articles related to these topics were included and discussed within this review. Results: Most studies examining biosimilar use in adult and pediatric noninfectious uveitis have evaluated the efficacy and safety of anti-tumor necrosis factor alpha (anti-TNF-α) agents, primarily adalimumab and infliximab biosimilars. Identified studies in both adults and children largely consisted of two designs: those comparing reference biologics with biosimilars and switch studies assessing outcomes following conversion to biosimilar therapy. Golimumab, certolizumab pegol, tocilizumab, sarilumab, and rituximab reference biologic studies offer promising results for treatment of NIU, but clinical trials evaluating biosimilar biologics lack in the literature. Compared with adult populations, pediatric cohorts treated with biosimilars for NIU are underrepresented in the literature. Conclusion: Current evidence suggests that adalimumab and infliximab biosimilars are effective and safe in comparison to reference biologics for treatment of NIU in the adult and pediatric populations. Expanded investigation in pediatric cohorts, including prospective clinical trials and inclusion of other biosimilar biologic agents are needed to address current gaps in evidence and to inform clinical decision-making.
16 April 2025 in Journal of American Association for Pediatric Ophthalmology and Strabismus